The FDA is exploring AI with OpenAI to potentially speed up drug approvals.

The U.S. Food and Drug Administration (FDA) is exploring the use of AI in drug evaluation and approval processes with AI company OpenAI. FDA Commissioner Marty Makary aims to modernize and expedite drug approvals. While no formal agreements have been made, the discussions focus on how AI could enhance the efficiency and effectiveness of drug reviews, potentially shortening the lengthy drug development timeline.